Top

Reactions Weekly

Published in:

01-02-2023 | Case report

Gadopiclenol

QT interval prolongation and maculopapular rash: 2 case reports

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Tsvetkova SB. Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in paediatric patients (2-17 years) undergoing MRI. Insights into Imaging 13 (Suppl. 4): 443 abstr. RPS 2612-2, 31 Dec 2022. Available from: URL: http://doi.org/10.1186/s13244-022-01337-x [abstract]

Title: Gadopiclenol
QT interval prolongation and maculopapular rash: 2 case reports
Publication date: 01-02-2023
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-33212-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gadopiclenol

QT interval prolongation and maculopapular rash: 2 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Azathioprine

Dabigatran-etexilate

Polymixin B

Tacrolimus

Antibacterials/immunouppressants

Dexamethasone/steroids